Frank Verwiel, M.D.

Frank Verwiel M.D. was President, CEO and Board member of Aptalis Pharma (previously known as Axcan Pharma (NASDAQ: AXCA)) from 2005 until 2014. Frank led the LBO that resulted in Aptalis to be acquired in 2008 by TPG Capital for $1.3 billion. In 2014 Forest Laboratories acquired Aptalis Pharma for $2.9 billion in an all-cash transaction.

Previously Frank was with Merck & Co. Inc. in various international senior management positions including Vice President, Hypertension, Worldwide Human Health Marketing. Frank was also Managing Director of Merck’s Dutch subsidiary and manufacturing operations. During his tenure with Servier Laboratories he was amongst others responsible for Servier’s Western European operations.

Frank is currently the Chairman of the Board of Directors of Intellia (NASDAQ: NTLA) and member of the Audit Committee and chair of the Corporate Nomination and Governance committee. He also serves as the Chairman of the Board of Directors of ObsEva (NASDAQ: OBSV) and the Audit Committee. Frank is a member of the Board of Directors of Bavarian Nordic (NASDAQ: BAVA) and Audit committee as well as the Nomination Compensation Committee. He is also a member of the Board of the privately-held gene-therapy company Capsida.

Frank was a member of the Board of Directors of InterMune (NASDAQ: ITMN) until its acquisition by Roche (2014). He was a member of the Board of Directors and Audit committee as well as chairman of the Compensation committee of AveXis (NASDAQ: AVXS) until its acquisition by Novartis (2018). Frank was a member of the Board of Directors and Audit committee as well as chairman of the Compensation committee of Achillion (NASDAQ: ACHN) until it was acquired by Alexion in 2020. Frank was a member of the Board of Directors and the Health Section Governing Board of BIO (Biotechnology Industry Organization).

Frank holds a Medical Doctor (M.D.) degree from Erasmus University, Rotterdam in the Netherlands and an MBA from INSEAD, Fontainebleau in France.